Non Small Cell Lung Cancer: Page 2

Biodesix touts VeriStrat test results
The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.
July 19, 2022
2019 09 09 20 46 2283 Lung Cancer 400
BillionToOne launches liquid biopsy products for research
The products are available for research use in select academic cancer centers.
July 7, 2022
2022 05 27 20 42 7840 Doctor Lab Test Bipoc 400
Biocartis, AstraZeneca to develop CDx for EGFR TKI treatment
The firms aim to obtain applicable premarket notification or approval from the U.S. Food and Drug Administration (FDA) for a CDx test on Biocartis' fully automated molecular Idylla platform.
June 21, 2022
2019 09 09 20 46 2283 Lung Cancer 400
Foundation Medicine gets FDA nod for NSCLC CDx
Rozlytrek is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) developed by Roche's Genentech.
June 8, 2022
2019 10 09 17 32 0093 Dna Cancer Cell 400
Stilla and Promega sign comarketing agreement
The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.
April 7, 2022
2020 04 14 22 00 7772 Business Men Handshake 400
Guardant wins new clearances in Japan for liquid biopsy test
The MHLW has cleared Guardant360 CDx for mutation profiling in patients with advanced solid tumors. In addition, it approved Guardant360 CDx as a companion diagnostic for identifying patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab (Keytruda). What's more, Guardant360 CDx has also been approved for patients with MSI-High advanced colorectal cancer who may benefit from nivolumab (Opdivo).
March 14, 2022
2022 03 08 19 56 8772 Clearance Stamp 400
Most Popular
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment
SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience
Roche reports flat diagnostics revenue growth for 2022
French point-of-care testing firm Biosynex to acquire Chembio Diagnostics for $17.2M
OIG report outlines challenges with CDC-supported COVID-19 vaccination programs
Insightec to launch new trials of Exablate Neuro
One study will evaluate the use of Exablate Neuro to treat patients with primary non-small cell lung cancer that has metastasized to the brain in conjunction with Keytruda, a humanized antibody immunotherapy. Exablate Neuro could be used to open up the blood-brain barrier to make immunotherapy agents like Keytruda more effective.
March 9, 2022
2022 03 10 18 19 1134 Mri Head 400
Invitae launches 2 IVD cancer tests in Europe
Both tests offer comprehensive genomic profiling and companion diagnostic use for solid tumor neoplasms, including non-small cell lung cancer, in tissue biopsy and where tissue is a limiting factor.
February 15, 2022
2022 01 12 21 29 6223 Europe Signpost 400
PierianDx, Biodesix partner on lung cancer diagnostics
PierianDx will provide its interpretation technology platform for use with Biodesix's newly launched GeneStrat NGS genomic test, a blood-based tumor profiling test that detects mutations -- including EGFR, ALK, and KRAS -- in patients with non-small cell lung cancer (NSCLC).
January 18, 2022
2019 09 05 21 14 7857 Heart Pulmonary Trunk 400
Lucence offers expanded cfRNA version LiquidHallmark
Researchers have found that adding RNA sequencing to DNA sequencing for tissue testing yields an additional 14% of "clinically actionable alterations," Lucence said. An internal study conducted by the firm found that "out of 112 non-small cell lung cancer samples, 29 fusions were detected with a combined cfDNA and cfRNA approach in plasma, compared with 20 fusions from cfDNA alone."
January 9, 2022
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400
Quest offers Biocept's liquid biopsy test
Biocept's Target Selector NGS Lung Panel helps with the genomic profiling of patients with advanced non-small cell lung cancer. The test helps physicians identify a potential treatment target and monitor the effectiveness of patients' treatments, according to Quest.
December 1, 2021
2019 05 13 16 12 9218 Lab Blood Woman2 400
FDA expands use of Qiagen lung cancer mutation test
Qiagen's polymerase chain reaction (PCR) test, the Therascreen KRAS RGQ PCR kit, is a tissue-based test that identifies the KAS KRAS G12C mutation in non-small cell lung cancer; the FDA approved the test for expanded use with Amgen's sotorasib (Lumakras). KRAS is one of the most frequently occurring mutations in this type of cancer.
June 1, 2021
2017 09 14 23 05 1167 Cancer Cell 400
Previous Page
Page 2 of 4
Next Page